Objectives Methods Results Conclusions Contact 64

Slides:



Advertisements
Similar presentations
Building on Patient Safety Clostridium difficile practice opportunities Mary Ellen Scales RN MSN CIC Baystate Medical Center.
Advertisements

The 10th International Congress of the Asian Society of Clinical Pathology and Laboratory Medicine September 10-11, 2009 in Ulaanbaatar Mongolia.
Cerebrospinal fluid Culture + Body Fluid Culture.
Divisional Meeting 15 th January 2009 Streptococcal Pharyngitis: A Systematic Review of the Predictive Value of Signs and Symptoms and the External Validation.
Diagnosing Clostridium difficile. Tim Planche St. George’s Healthcare NHS Trust St. George’s, University of London.
TechLab Diarrheal Diseases in Underdeveloped Countries Worldwide Problem More than 10,000 deaths per day On average, about 18 diarrheal episodes per year.
Welcome to Journal club Dr. Md. Abul Hossain Khan Honorary Trainee Department of microbiology, MMC A Comparative Study of Typhidot and Widal Test in Patients.
NEW Product MAY 2006 STREPTO B ID NEW chromogenic media available ! STREPTO B ID NEW PRODUCT in the bMx offer SECOND in the NEW PREVENTION range dedicated.
STUDY DESIGN FOR DIAGNOSTIC STUDY FOR MELIOIDOSIS Dr Direk Limmathurotsakul, MD MSc PhD.
Diagnostic Microbiology and Immunology
Alfred DeMaria, Jr., M.D. Medical Director Bureau of Infectious Disease Prevention, Response and Services State Epidemiologist C. Difficile Testing Recommendations.
Alere TM HIV Combo Yuko Tamanoue, Product Development Department.
How to Critically Appraise A Diagnostic Article Sandy De Groote.
Background In 2009, the Centers for Disease Control and Prevention (CDC) introduced a module in the National Healthcare Safety Network (NHSN) allowing.
The Connecticut Experience with non-O157 STEC “Seek and Ye Shall Find” Sharon Hurd, MPH October 17, 2007 Connecticut Emerging Infections Program FoodNet.
Welcome to the GHA Infection Prevention Power Hour June 19, 2014.
Point of Care Testing – Clostridium difficle Amita Patel Guy’s and St Thomas’ NHS Foundation Trust.
CURRENT STATUS Consultant Microbiologist with additional responsibilities of Head of The Department and Director of National Leptospirosis Reference Unit.
RESULTS INTRODUCTION METHODS CONCLUSION  Since the early 90’s Enterococcus faecium resistant to Glycopeptides (GRE) have emerged in several French hospitals.
CONCLUSIONS Amended Abstract Detection of GBS Directly from ESwab Collected Samples Using the BD MAX™ GBS Assay Suzane Silbert, Talita T. Rocchetti, Alicia.
Value of PCR: A Pertussis Outbreak in a Football Team Sharmila Shah 1, Mohammed Haque 1, John Kornblum 2, Lillian Lee 2, Allison Scaccia 1, Jane R. Zucker.
INTRODUCTION Assessment of a real-time PCR for the identification and characterisation of Verocytotoxigenic E. coli (VTEC) Claire Jenkins, Andy J. Lawson,
Healthcare-Associated Infection (HAI) and the Role of Diagnostic Testing 1 Date, time, presenter etc. goes here For external use © 2014 Alere. All rights.
COMPARISON OF LABORATORY DIAGNOSTIC PROCEDURES FOR DETECTION OF MYCOPLASMA PNEUMONIAE IN COMMUNITY OUTBREAKS KATHLEEN A. THURMAN, NICHOLAS D. WALTER, STEPHANIE.
Shiga Toxin E. coli Rapid detection is key!. Intestinal Diseases Difficult to diagnose clinically – Most have very similar symptoms Treatment & patient.
Point of Care Diagnostics for Hospital Acquired Infections (HAIs): Health Economics Perspective Detection & Identification of Infectious Agents (DIIA)
Clostridium difficile Infection Fellow 이시내. Clostridium difficile  An anaerobic gram-positive, spore-forming, toxin-producing bacillus.  Transmitted.
Title of the Change Project
Reducing the Risk of Clostridium difficile Infection:
Xth International Conference on AIDS and STD in Africa, December 1997
Comparing Conventional to Point-of-Care (POC) Early Infant Diagnosis (EID): Pre and post intervention data from a multi-country evaluation. Flavia Bianchi,
Evaluation of Various Laboratory Methods for the Diagnosis of Clostridium difficile Infection Yousun Chung1, Ji Yeon Sung1, Ho Eun Chang2, Soon Hee Choi2,
PREMARKET EVALUATION OF THE BD MAXTM CLOSTRIDIUM DIFFICILE PCE ASSAY
Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.
Evolution in the Type of Diagnostic Tests Used in Quebec, Canada,
Prevalence of Positive Widal test among Healthy Personnel in Kerbala
Impact of the Type of Diagnostic Assay on Clostridium difficile Infection and Complication Rates in a Mandatory Reporting Program Yves Longtin, Sylvie.
Table 1 Characteristics of the 968 Women in the Study Group
Evaluation of the BD MAX™ MRSA XT Assay in a Clinical Laboratory
Xth International Conference on AIDS and STD in Africa, December 1997
C. difficile Detection and the Importance of Proper Specimen Collection and Testing [Name] [Title]
ASM 2017 Microbe Annual Meeting Sunday-507
Rainbow O157 Agar-Black colonies are E. coli O157
CDI Collaborative Susan Irving, RN, CIC, MPH
D th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, Washington, DC Evaluation of a Rapid PBP2’ Agglutination.
The 5D framework: a clinical primer for fecal microbiota transplantation to treat Clostridium difficile infection  Jessica R. Allegretti, MD, MPH, Zain.
Cost utility of alternative Carbapenemase
CNISP & CIHI MRSA infection rate comparison Preliminary results
Laboratory Diagnosis of Clostridium difficile Infection
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
F. Barbut, M. Delmée, J. S. Brazier, J. C. Petit, I. R. Poxton, M
Clinical characteristics and outcome of patients with Clostridium difficile infection diagnosed by PCR versus a three-step algorithm  C. Beaulieu, L.-L.
Patricia Butterfield & Naomi Chaytor October 18th, 2017
Comparing the economic and health benefits of different approaches to diagnosing Clostridium difficile infection  Sarah M. Bartsch, Craig A. Umscheid,
Low sensitivity of fecal toxin A/B enzyme immunoassay for diagnosis of Clostridium difficile infection in immunocompromised patients  S. Erb, R. Frei,
F. Barbut, L. Surgers, C. Eckert, B. Visseaux, M. Cuingnet, C
M.H. Wilcox  Clinical Microbiology and Infection 
Cerebrospinal fluid Culture
Application of Nuclear Magnetic Resonance to Detect Toxigenic Clostridium difficile from Stool Specimens  Paul Yang, Sara Hash, Katherine Park, Charlene.
European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection  M.J.T.
R. Alonso, C. Muñoz, T. Peláez, E. Cercenado, M. Rodríguez-Creixems, E
Metabolic PHENOTYPE by NMR spectroscopy: A biomarker for lung CANCER
Detection of nosocomial Clostridium difficile infections with toxigenic strains despite negative toxin A and B testing on stool samples  J. Stahlmann,
N. Jazmati, M. Hellmich, B. Ličanin, G. Plum, A.J. Kaasch 
Toward a More Perfect World
Clostridium difficile toxin testing by National Health Service (NHS) acute Trusts in England: 2008–2013  S.M. Gerver, A.P. Johnson, R.J. Hope  Clinical.
Cerebrospinal fluid Culture
Trends and changes in Clostridium difficile diagnostic policies and their impact on the proportion of positive samples: a national survey  A. Adler, Y.
C. diff Testing Stewardship
UNMH’s hospital acquired C
Presentation transcript:

Objectives Methods Results Conclusions Contact 64 Laboratory testing for Clostridium difficile infection: looking for a good algorithm. K. Vandebroek, N. Graindor, G. De Sutter, G. Coppens, E. Oris Ziekenhuis Oost-Limburg, Genk BSIM 21st Annual congress, 2-3 December 2016 Objectives Methods Detection of toxigenic C. difficile with culture and toxin A/B antigen detection on positive culture is a very reliable but time consuming method, with a long turnaround time (TAT) of at least 48 hours. Therefore we evaluated a new diagnostic algorithm with the aim to maintain test validity and to shorten the TAT. Consecutive fluid stool specimens of patients with suspected Clostridium difficile infection (CDI) were evaluated between December 2014 and February 2015. All samples (107) were tested with the C. DIFF QUIK CHEK antigen test (Alere), a rapid enzyme immunoassay to detect glutamate dehydrogenase (GDH), and cultured on a Clostridium agar plate (BioMérieux) with identification of the suspected isolates on Maldi Biotyper (Bruker). Between March 2015 and April 2016, only GDH positive samples (103) were both tested with the Xpert C. difficile PCR test (Cepheid) and cultured with toxin A/B detection (Quik chek, Alere) on the isolate. Table 2: Toxin antigen detection - culture - PCR on GDH positive samples Table 1: GDH antigen testing compared with culture Table 3: Cost calculation of the classic and the new algorithm. Results Conclusions In the first part of the study (see table 1), we compared the GDH antigen test with culture as a reference method on 107 specimens. A sensitivity of 93% and a specificity of 100% was observed. With a prevalence rate for Clostridium difficile of 14%, the GDH screening had a positive predictive value of 100% and a negative predictive value of 99%. In the second part, 103 positive GDH samples were analyzed prospectively (see table 2). Only 83,5% (86) of them were culture positive. This is in contradiction with previous results, probably due to the low number of GDH positive samples (15) in the first part of the study. Of the culture positive samples, 43% (37) were positive with the toxin A/B antigen test after 48 hours all of which were confirmed with the PCR test. On the culture positive, toxin A/B negative samples (49) after 48 hours of incubation, another 43% (21) were determined positive with PCR. Of the culture negative samples (17), six turned out positive with PCR. On a subset (30) of culture positive specimens, 3 additional samples (10%) were found positive when the toxin A/B antigen test was performed after a culturing period of 72 hours. The toxin A/B detection (Quik chek, Alere) directly on stool samples was not considered for the testing algorithm, because a lack of sensitivity in preliminary observations. With our previous algorithm consisting of culturing C. difficile followed by toxin A/B antigen detection, 43% (37) of the positive cultures were claimed positive for toxigenic C. difficile after 48 hours. A longer incubation period of 24 hours increased the sensitivity of the toxin A/B antigen test by 10%. With the new testing algorithm, stool samples were screened with the sensitive and specific GDH antigen test. If positive, a PCR was performed. Although this new algorithm has an additional laboratory cost, a higher rate of toxigenic C. difficile was detected (62% instead of 36%) and results could be delivered within 24 hours. We claim that this new testing algorithm is more efficient in reducing the risk of nosocomial spread and provides a faster intervention towards the patient. Contact Katrien Vandebroek, M. Sc.: katrien.vandebroek@zol.be 64